11:11 AM EST - Theralase Technologies Inc. : Announced today that Theralase's Rutherrin® Photo Dynamic Therapy has been shown to increase its efficacy in cancer treatments, inducing a cancer specific immune response, by switching the so-called "Don't eat me" signal to an "Eat me" signal on treated human glioblastoma cells. Theralase Technologies Inc.
shares V.TLT are trading up $0.025 at $0.36.
